Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
P/B ratio for Madrigal Pharmaceuticals, Inc. (MDGL)
P/B ratio as of 2023: 10.67
According to Madrigal Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 10.67. At the end of 2022 the company had a P/B ratio of 25.20.
P/B ratio history for Madrigal Pharmaceuticals, Inc. from 2001 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 10.67 |
| 2022 | 25.20 |
| 2021 | 7.15 |
| 2020 | 7.16 |
| 2019 | 3.37 |
| 2018 | 3.50 |
| 2017 | 6.17 |
| 2016 | 2.13 |
| 2015 | 0.04 |
| 2014 | 4.01 |
| 2013 | 7.58 |
| 2012 | 7.14 |
| 2011 | 14.92 |
| 2010 | 10.52 |
| 2009 | 6.88 |
| 2008 | -3.51 |
| 2007 | 8.74 |
| 2006 | -115.85 |
| 2005 | 3.85 |
| 2004 | 1.44 |
| 2003 | 2.58 |
| 2002 | 0.00 |
| 2001 | 9.71 |